NERVGEN PHARMA CORP (NGEN.CA) Stock Earnings & Estimates
TSX-V:NGEN - CA64082X2032 - Common Stock
3.71 CAD
+0.39 (+11.75%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 1,180.28% | N/A 249.99% | |||||||||
| EBITDA YoY % growth | -11.8K | -1.339M -11,244.92% | -9.826M -634.01% | -11.156M -13.54% | -12.769M -14.45% | -23.425M -83.45% | -17.632M 24.73% | -24.848M -40.93% | N/A -13.40% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.8K | -1.359M -11,412.71% | -9.864M -626.12% | -11.196M -13.50% | -12.811M -14.43% | -23.54M -83.74% | -17.777M 24.48% | -24.932M -40.25% | N/A -206.29% | N/A -2.70% | N/A 130.26% | N/A 1,391.32% | N/A 15.45% | N/A 19.44% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | -0.42 -34.14% | N/A 25.45% | -0.35 -11.79% | N/A 2.85% | N/A 52.48% | N/A -25.00% | N/A 105.00% | N/A 16,365.00% | N/A 121.95% |
All data in CAD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.04 42.29% | -0.04 68.92% | -0.05 15.83% | -0.05 61.15% | -0.04 | -0.04 |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
All data in CAD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.13 -18.18% | -0.05 | -0.08 | -157.43% |
| Q1 2025 Q2Q % growth | -0.06 -50.00% | -0.09 | 0.03 | 33.99% |
| Q4 2024 Q2Q % growth | -0.13 | -0.09 | -0.04 | -51.43% |
| Q3 2024 Q2Q % growth | -0.07 | -0.09 | 0.02 | 22.99% |
| Q2 2024 Q2Q % growth | -0.11 | -0.09 | -0.02 | -21.01% |
| Q1 2024 Q2Q % growth | -0.04 | -0.07 | 0.03 | 43.42% |
| Q4 2022 Q2Q % growth | -0.10 -11.11% | -0.12 | 0.02 | 17.49% |
| Q3 2022 Q2Q % growth | -0.08 11.11% | -0.14 | 0.06 | 43.42% |
| Q2 2022 Q2Q % growth | -0.13 | -0.11 | -0.02 | -17.01% |
| Q1 2022 Q2Q % growth | -0.11 | -0.08 | -0.03 | -36.14% |
| Q4 2021 Q2Q % growth | -0.09 | -0.09 | 0.00 | 0.99% |
| Q3 2021 Q2Q % growth | -0.09 | -0.07 | -0.02 | -27.30% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 37.5% | 18.87% | 18.87% |
| Revenue | N/A | N/A | N/A | N/A |